Clinical readout

J&J details patient priorities and saliva data for nipocalimab in Sjögren's

Exit interviews from DAHLIAS, a phase 2 trial, found dry mouth was the symptom patients most wanted improved. In an exploratory endpoint, 33% of patients on high-dose nipocalimab saw salivary flow rise by half or more at week 24, against 16% on placebo. Johnson & Johnson is running two phase 3 trials in the disease.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call